Skip to main content
SpringerLink
Log in
Book cover

Antimicrobial Resistance in Developing Countries pp 137–156Cite as

Antifungal Drug Resistance in Developing Countries

  • Chapter
  • First Online:

  • 2248 Accesses

Abstract

Opportunistic fungal infections are a major cause of morbidity and mortality in immunosuppressed patients; and in HIV-positive individuals, infections due to Candida, Cryptococcus, and Pneumocystis are AIDS-defining illnesses. The widespread use of antifungal drugs, particularly triazole drugs, has led to the emergence of primary resistance, which largely reflects infection with inherently less susceptible strains. Secondary resistance in normally susceptible strains also occurs and involves a variety of mechanisms including target site modification and drug efflux transporters. Resistance is a clinical management issue, but it has remained relatively constant in most developed countries. In developing countries, resistance is minimal due to limited antifungal therapy. However, as access to these drugs increases, it is particularly important to evaluate trends that reflect evolving resistance issues observed elsewhere, especially among individuals with HIV/AIDS.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abdel-Salam, H. A. 2005. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs. Mycoses 48: 327–32.

    Article  PubMed  CAS  Google Scholar 

  • Ampel, N. M. 1996. Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis 2: 109–16.

    Article  PubMed  CAS  Google Scholar 

  • Balajee, S. A., J. L. Gribskov, E. Hanley et al. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 4: 625–32.

    Article  PubMed  CAS  Google Scholar 

  • Bicanic, T., T. Harrison, A. Niepieklo et al. 2006. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 43: 1069–73.

    Article  PubMed  CAS  Google Scholar 

  • Bicanic, T., T. S. Harrison 2004. Cryptococcal meningitis. Br Med Bull 72: 99–118.

    Article  PubMed  Google Scholar 

  • Bii, C. C., K. Makimura, S. Abe et al. 2007. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 50(1): 25–30.

    Article  PubMed  CAS  Google Scholar 

  • Blignaut, E., M. E. Botes, H. L. Nieman 1999. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 54: 605–8.

    PubMed  CAS  Google Scholar 

  • Blumberg, H. M., W. R. Jarvis, J. M. Soucie et al. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33: 177–86.

    Article  PubMed  CAS  Google Scholar 

  • Bow, E. J. 2005. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 43 Suppl 1: S277–87.

    Google Scholar 

  • Brion, L. P., S. E. Uko, D. L. Goldman 2007. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 54: 521–9.

    Article  PubMed  Google Scholar 

  • Broughton, M. C., M. Bard, N. D. Lees 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34: 75–83.

    Article  PubMed  CAS  Google Scholar 

  • Cartledge, J. D., J. Midgley, B. G. Gazzard 1997. Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case- control study. Genitourin Med 73: 471–4.

    PubMed  CAS  Google Scholar 

  • Chaiwarith, R., N. Charoenyos, T. Sirisanthana, K. Supparatpinyo 2007. Discontinuation of secondary prophylaxis against Penicilliosis marneffei in AIDS patients after HAART. AIDS 21: 365–7.

    Article  PubMed  Google Scholar 

  • Chakaya, J. M., C. Bii, L. Ng'ang'a et al. 2003. Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. East Afr Med J 80: 30–5.

    PubMed  CAS  Google Scholar 

  • Chen, Y. C., S. C. Chang, K. T. Luh, W. C. Hsieh 2003. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 52: 71–7.

    Article  PubMed  CAS  Google Scholar 

  • Colombo, A. L., T. Guimaraes, L. R. Silva et al. 2007. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol 28: 570–6.

    Article  PubMed  Google Scholar 

  • Coste, A. T., M. Karababa, F. Ischer et al. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 3: 1639–52.

    Article  PubMed  CAS  Google Scholar 

  • da Matta, D. A., L. P. de Almeida, A. M. Machado et al. 2007. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995–2003. Diagn Microbiol Infect Dis 57: 399–404.

    Article  PubMed  CAS  Google Scholar 

  • Dallabetta, G. A., P. G. Miotti, J. D. Chiphangwi et al. 1995. Traditional vaginal agents: use and association with HIV infection in Malawian women. AIDS 9: 293–7.

    PubMed  CAS  Google Scholar 

  • Dannaoui, E., E. Borel, F. Persat et al. 2000. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 49: 601–6.

    PubMed  CAS  Google Scholar 

  • De Hertogh, B., F. Hancy, A. Goffeau, P. V. Baret 2006. Emergence of species-specific transporters during evolution of the hemiascomycete phylum. Genetics 172: 771–81.

    Article  PubMed  CAS  Google Scholar 

  • Diekema, D. J., S. A. Messer, R. J. Hollis et al. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41: 3623–6.

    Article  PubMed  CAS  Google Scholar 

  • Dodgson, A. R., K. J. Dodgson, C. Pujol et al. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother 48: 2223–7.

    Article  PubMed  CAS  Google Scholar 

  • Eggimann, P., J. Garbino, D. Pittet 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3: 685–702.

    Article  PubMed  Google Scholar 

  • Fidel, P. L., Jr., J. A. Vazquez, J. D. Sobel 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 12: 80–96.

    PubMed  Google Scholar 

  • Gallis, H. A., R. H. Drew, W. W. Pickard 1990. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12: 308–29.

    PubMed  CAS  Google Scholar 

  • Garcia-Effron, G., E. Mellado, A. Gomez-Lopez et al. 2005. Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother 49: 2119–21.

    Article  PubMed  CAS  Google Scholar 

  • Gardiner, R. E., P. Souteropoulos, S. Park, D. S. Perlin 2005. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 43 Suppl 1: S299–305.

    Google Scholar 

  • Girish Kumar, C. P., A. M. Hanafy, M. Katsu et al. 2006. Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India. Mycopathologia 161: 153–9.

    Article  PubMed  CAS  Google Scholar 

  • Goldman, M., P. C. Johnson, G. A. Sarosi 1999. Fungal pneumonias. The endemic mycoses. Clin Chest Med 20(3): 507–19.

    Article  PubMed  CAS  Google Scholar 

  • Gudlaugsson, O., S. Gillespie, K. Lee et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172–7.

    Article  PubMed  Google Scholar 

  • Hakki, M., J. F. Staab, K. A. Marr 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50: 2522–4.

    Article  PubMed  CAS  Google Scholar 

  • Harry, J. B., J. L. Song, C. N. Lyons, T. C. White 2002. Transcription initiation of genes associated with azole resistance in Candida albicans. Med Mycol 40: 73–81.

    PubMed  CAS  Google Scholar 

  • Helweg-Larsen, J., T. L. Benfield, J. Eugen-Olsen et al. 1999. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 354: 1347–51.

    Article  PubMed  CAS  Google Scholar 

  • Hope, W. W., L. Tabernero, D. W. Denning, M. J. Anderson 2004. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother 48: 4377–86.

    Article  PubMed  CAS  Google Scholar 

  • Howard, S. J., I. Webster, C. B. Moore et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28: 450–3.

    Article  PubMed  CAS  Google Scholar 

  • Ikeda, R., T. Sugita, E. S. Jacobson, T. Shinoda 2003. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol 47: 271–7.

    PubMed  CAS  Google Scholar 

  • Iliades, P., S. R. Meshnick, I. G. Macreadie 2005a. Analysis of Pneumocystis jirovecii DHPS alleles implicated in sulfamethoxazole resistance using an Escherichia coli model system. Microb Drug Resist 11: 1–8.

    Google Scholar 

  • Iliades, P., S. R. Meshnick, I. G. Macreadie 2005b. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob Agents Chemother 49: 741–8.

    Google Scholar 

  • Imhof, A., S. A. Balajee, D. N. Fredricks et al. 2004. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39: 743–6.

    Article  PubMed  Google Scholar 

  • Johnson, E. M., D. W. Warnock, J. Luker et al. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 35: 103–14.

    Article  PubMed  CAS  Google Scholar 

  • Kahn, J. N., G. Garcia-Effron, M. J. Hsu et al. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 51: 1876–8.

    Article  PubMed  CAS  Google Scholar 

  • Kazanjian, P., W. Armstrong, P. A. Hossler et al. 2001. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis 183: 819–22.

    Article  PubMed  CAS  Google Scholar 

  • Kazanjian, P. H., D. Fisk, W. Armstrong et al. 2004. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J Infect Dis 189: 1684–7.

    Article  PubMed  Google Scholar 

  • Kelly, S. L., D. C. Lamb, D. E. Kelly et al. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 400: 80–2.

    Article  PubMed  CAS  Google Scholar 

  • Kessl, J. J., P. Hill, B. B. Lange et al. 2004. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J Biol Chem 279: 2817–24.

    Article  PubMed  CAS  Google Scholar 

  • Kovacs, J. A., V. J. Gill, S. Meshnick, H. Masur 2001. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 286: 2450–60.

    Article  PubMed  CAS  Google Scholar 

  • Kwon-Chung, K. J. 1994. Phylogenetic spectrum of fungi that are pathogenic to humans. Clin Infect Dis 19 Suppl 1: S1–7.

    Google Scholar 

  • Laverdiere, M., R. G. Lalonde, J. G. Baril et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57: 705–8.

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz, L. D., H. R. Ashbee, E. G. Evans et al. 2001. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 40: 27–33.

    Article  PubMed  CAS  Google Scholar 

  • Lionakis, M. S., R. E. Lewis, H. A. Torres et al. 2005. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52: 15–20.

    Article  PubMed  CAS  Google Scholar 

  • Marr, K. A., R. A. Carter, F. Crippa et al. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34: 909–17.

    Article  PubMed  Google Scholar 

  • Marr, K. A., C. N. Lyons, K. Ha et al. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 45: 52–9.

    Article  PubMed  CAS  Google Scholar 

  • Martins, M. D., J. H. Rex 1996. Resistance to antifungal agents in the critical care setting: problems and perspectives. New Horiz 4: 338–44.

    PubMed  CAS  Google Scholar 

  • Marty, F. M., L. A. Cosimi, L. R. Baden 2004. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350: 950–2.

    Article  PubMed  CAS  Google Scholar 

  • Mathema, B., E. Cross, E. Dun et al. 2001. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 33: E23–7.

    Article  PubMed  CAS  Google Scholar 

  • Meis, J., M. Petrou, J. Bille et al. 2000. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group. Diagn Microbiol Infect Dis 36: 215–23.

    Article  PubMed  CAS  Google Scholar 

  • Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli et al. 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 48: 2747–50.

    Article  PubMed  CAS  Google Scholar 

  • Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51: 1897–904.

    Article  PubMed  CAS  Google Scholar 

  • Meshnick, S. R. 1999. Drug-resistant Pneumocystis carinii. Lancet 354: 1318–9.

    Article  PubMed  CAS  Google Scholar 

  • Messer, S. A., R. N. Jones, T. R. Fritsche 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 44: 1782–7.

    Article  PubMed  CAS  Google Scholar 

  • Miller, C. D., B. W. Lomaestro, S. Park, D. S. Perlin 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26: 877–80.

    Article  PubMed  Google Scholar 

  • Miller, R. F. 1999. Pneumocystis carinii infection in non-AIDS patients. Curr Opin Infect Dis 12: 371–7.

    PubMed  CAS  Google Scholar 

  • Moosa, M. Y., G. J. Alangaden, E. Manavathu, P. H. Chandrasekar 2002. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother 49: 209–13.

    Article  PubMed  CAS  Google Scholar 

  • Morris, A., L. A. Kingsley, G. Groner et al. 2004a. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 18: 793–8.

    Article  PubMed  Google Scholar 

  • Morris, A., J. D. Lundgren, H. Masur et al. 2004b. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 10: 1713–20.

    PubMed  Google Scholar 

  • Nahimana, A., M. Rabodonirina, J. Bille et al. 2004. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 48: 4301–5.

    Article  PubMed  CAS  Google Scholar 

  • Nahimana, A., M. Rabodonirina, G. Zanetti et al. 2003. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis 188: 1017–23.

    Article  PubMed  CAS  Google Scholar 

  • Narasimhan, M., A. J. Posner, V. A. DePalo et al. 2004. Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 125: 1800–4.

    Article  PubMed  Google Scholar 

  • Nascimento, A. M., G. H. Goldman, S. Park et al. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 47: 1719–26.

    Article  PubMed  CAS  Google Scholar 

  • Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris et al. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100: 617–23.

    Article  PubMed  CAS  Google Scholar 

  • Nucci, M., A. L. Colombo 2002. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 21: 209–11.

    Article  PubMed  CAS  Google Scholar 

  • Ohmit, S. E., J. D. Sobel, P. Schuman et al. 2003. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 188: 118–27.

    Article  PubMed  Google Scholar 

  • Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47: 3149–54.

    Article  PubMed  CAS  Google Scholar 

  • Park, S., R. Kelly, J. N. Kahn et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49: 3264–73.

    Article  PubMed  CAS  Google Scholar 

  • Pepin, J., F. Sobela, N. Khonde et al. 2006. The syndromic management of vaginal discharge using single-dose treatments: a randomized controlled trial in West Africa. Bull World Health Organ 84: 729–38.

    Article  PubMed  Google Scholar 

  • Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick et al. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676–84.

    Article  PubMed  CAS  Google Scholar 

  • Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10: 121–30.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A. 2000. Antifungal susceptibility testing: progress and future developments. Braz J Infect Dis 4: 55–60.

    PubMed  CAS  Google Scholar 

  • Pfaller, M. A., L. Boyken, R. J. Hollis et al. 2005a. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 43: 3807–10.

    Google Scholar 

  • Pfaller, M. A., D. J. Diekema 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10 Suppl 1: 11–23.

    Article  Google Scholar 

  • Pfaller, M. A., D. J. Diekema 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133–63.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., D. J. Diekema, D. L. Gibbs et al. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45: 1735–45.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., D. J. Diekema, R. N. Jones et al. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39: 3254–9.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., D. J. Diekema, M. Mendez et al. 2006a. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 44: 3551–6.

    Google Scholar 

  • Pfaller, M. A., D. J. Diekema, S. A. Messer et al. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41: 1440–6.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., D. J. Diekema, M. G. Rinaldi et al. 2005b. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43: 5848–59.

    Google Scholar 

  • Pfaller, M. A., D. J. Diekema, D. J. Sheehan 2006b. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19: 435–47.

    Google Scholar 

  • Pfaller, M. A., R. N. Jones, G. V. Doern et al. 1999a. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35: 19–25.

    Google Scholar 

  • Pfaller, M. A., R. N. Jones, G. V. Doern et al. 1998a. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 36: 1886–9.

    Google Scholar 

  • Pfaller, M. A., R. N. Jones, G. V. Doern et al. 2000. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. Antimicrob Agents Chemother 44: 747–51.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., R. N. Jones, S. A. Messer et al. 1998b. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 30: 121–9.

    Google Scholar 

  • Pfaller, M. A., S. A. Messer, L. Boyken et al. 2004a. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48: 201–5.

    Google Scholar 

  • Pfaller, M. A., S. A. Messer, L. Boyken et al. 2005c. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 43: 2163–7.

    Google Scholar 

  • Pfaller, M. A., S. A. Messer, L. Boyken et al. 2004b. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 42: 3142–6.

    Google Scholar 

  • Pfaller, M. A., S. A. Messer, R. J. Hollis 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn Microbiol Infect Dis 20: 127–33.

    Article  PubMed  CAS  Google Scholar 

  • Pfaller, M. A., S. A. Messer, R. J. Hollis et al. 1999b. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33: 217–22.

    Google Scholar 

  • Pujol, C., M. A. Pfaller, D. R. Soll 2004. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother 48: 262–6.

    Article  PubMed  CAS  Google Scholar 

  • Rangel-Frausto, M. S., T. Wiblin, H. M. Blumberg et al. 1999. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29: 253–8.

    Article  PubMed  CAS  Google Scholar 

  • Rex, J. H., M. A. Pfaller, J. N. Galgiani et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 24: 235–47.

    PubMed  CAS  Google Scholar 

  • Richter, S. S., R. P. Galask, S. A. Messer et al. 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43: 2155–62.

    Article  PubMed  CAS  Google Scholar 

  • Riggle, P. J., C. A. Kumamoto 2006. Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site. Eukaryot Cell 5: 1957–68.

    Article  PubMed  CAS  Google Scholar 

  • Rocha, E. M. F., G. Garcia-Effron, S. Park, D. S. Perlin 2007. A Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 51: 4174–76.

    Google Scholar 

  • Rogers, B., A. Decottignies, M. Kolaczkowski et al. 2001. The pleiotropic drug ABC transporters from Saccharomyces cerevisiae. J Mol Microbiol Biotechnol 3: 207–14.

    PubMed  CAS  Google Scholar 

  • Ruffini, D. D., S. A. Madhi 2002. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 16: 105–12.

    Article  PubMed  Google Scholar 

  • Sabra, R., R. A. Branch 1990. Amphotericin B nephrotoxicity. Drug Saf 5: 94–108.

    Article  PubMed  CAS  Google Scholar 

  • Saiman, L., E. Ludington, J. D. Dawson et al. 2001. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 20: 1119–24.

    Article  PubMed  CAS  Google Scholar 

  • Samaranayake, Y. H., L. P. Samaranayake, P. C. Tsang et al. 2001. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort. J Oral Pathol Med 30: 336–46.

    Article  PubMed  CAS  Google Scholar 

  • Sandven, P. 1999. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J Clin Microbiol 37: 3856–9.

    PubMed  CAS  Google Scholar 

  • Sanglard, D. 2002. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 5: 379–85.

    Article  PubMed  CAS  Google Scholar 

  • Sanglard, D., F. C. Odds 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73–85.

    Article  PubMed  CAS  Google Scholar 

  • Sanguinetti, M., B. Posteraro, B. Fiori et al. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49: 668–79.

    Article  PubMed  CAS  Google Scholar 

  • Sar, B., D. Monchy, M. Vann et al. 2004. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54: 563–5.

    Article  PubMed  CAS  Google Scholar 

  • Selmecki, A., A. Forche, J. Berman 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 31: 367–70.

    Article  CAS  Google Scholar 

  • Sobel, J. D. 2002. Pathogenesis of recurrent Vulvovaginal Candidiasis. Curr Infect Dis Rep 4: 514–519.

    Article  PubMed  Google Scholar 

  • Sobel, J. D., S. E. Ohmit, P. Schuman et al. 2001. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 183: 286–93.

    Article  PubMed  CAS  Google Scholar 

  • Sobel, J. D., S. E. Ohmit, P. Schuman et al. 2000. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 183: 286–293.

    Article  PubMed  Google Scholar 

  • Standards, NCCL. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved Standard – Second Edition NCCLS document M27-A2. National Committee for Clinical Laboratory Standards. Wayne, PA.

    Google Scholar 

  • Stein, C. R., C. Poole, P. Kazanjian, S. R. Meshnick 2004. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 10: 1760–5.

    PubMed  CAS  Google Scholar 

  • Steinbach, W. J., D. K. Benjamin, Jr., D. P. Kontoyiannis et al. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39: 192–8.

    Article  PubMed  Google Scholar 

  • Stiefel, U., C. J. Donskey 2004. The role of the intestinal tract as a source for transmission of nosocomial pathogens. Curr Infect Dis Rep 6: 420–425.

    Article  PubMed  Google Scholar 

  • Takahashi, T., M. Goto, T. Endo et al. 2002. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 51: 611–4.

    PubMed  Google Scholar 

  • Tumbarello, M., E. Tacconelli, K. de Gaetano Donati et al. 1999. Candidemia in HIV-infected subjects. Eur J Clin Microbiol Infect Dis 18: 478–83.

    Article  PubMed  CAS  Google Scholar 

  • Vanden Bossche, H., F. Dromer, I. Improvisi et al. 1998. Antifungal drug resistance in pathogenic fungi. Med Mycol 36(Suppl 1): 119–28.

    PubMed  CAS  Google Scholar 

  • Vermes, A., H. J. Guchelaar, J. Dankert 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46: 171–9.

    Article  PubMed  CAS  Google Scholar 

  • Vermitsky, J. P., T. D. Edlind 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 48: 3773–81.

    Article  PubMed  CAS  Google Scholar 

  • Visconti, E., E. Ortona, P. Mencarini et al. 2001. Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. Int J Antimicrob Agents 18: 547–51.

    Article  PubMed  CAS  Google Scholar 

  • Wakiec, R., R. Prasad, J. Morschhauser et al. 2007. Voriconazole and multidrug resistance in Candida albicans. Mycoses 50: 109–15.

    Article  PubMed  CAS  Google Scholar 

  • Walsh, T. J., A. H. Groll 1999. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1: 247–61.

    Article  PubMed  CAS  Google Scholar 

  • Walsh, T. J., V. Yeldandi, M. McEvoy et al. 1998. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42: 2391–8.

    PubMed  CAS  Google Scholar 

  • Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20: 1531–4.

    PubMed  CAS  Google Scholar 

  • White, T. C., S. Holleman, F. Dy et al. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704–13.

    Article  PubMed  CAS  Google Scholar 

  • White, T. C., K. A. Marr, R. A. Bowden 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382–402.

    PubMed  CAS  Google Scholar 

  • WHO. 2006. WHO expert consultation on cotrimoxazole prophylaxis in HIV infection. Geneva, World health Organization: 1–34.

    Google Scholar 

  • Wingard, J. R. 2005. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 17: 89–92.

    Article  PubMed  Google Scholar 

  • Wisplinghoff, H., T. Bischoff, S. M. Tallent et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309–17.

    Article  PubMed  Google Scholar 

  • Wisplinghoff, H., H. Seifert, S. M. Tallent et al. 2003. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 22: 686–91.

    PubMed  Google Scholar 

  • Wissmann, G., M. J. Alvarez-Martinez, S. R. Meshnick et al. 2006. Absence of dihydropteroate synthase mutations in Pneumocystis jirovecii from Brazilian AIDS patients. J Eukaryot Microbiol 53: 305–7.

    Article  PubMed  CAS  Google Scholar 

  • Wong-Beringer, A., R. A. Jacobs, B. J. Guglielmo 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27: 603–18.

    Article  PubMed  CAS  Google Scholar 

  • Xess, I., N. Jain, F. Hasan et al. 2007. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 35: 256–9.

    Article  PubMed  CAS  Google Scholar 

  • Zar, H. J. 2001. Pneumocystis carinii pneumonia (PCP) in HIV-infected African children. SADJ 56: 617–9.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Public Health Research Institute, New Jersey Medical School/UMDNJ at the International Center for Public Health (ICPH), 07103-3535, Newark, NJ, USA

    David S. Perlin

Authors
  1. David S. Perlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Perlin .

Editor information

Editors and Affiliations

  1. Advisor Alliance for the Prudent Use of, Tufts University, Kneeland St. 75, Boston, 02111, U.S.A.

    Aníbal de J. Sosa

  2. Dept. Zoology, Makerere University Kampala, Kampala, Uganda

    Denis K. Byarugaba

  3. Fundación Lusara, Playa Rosarito 353, Mexico, 08810, Mexico

    Carlos F. Amábile-Cuevas

  4. Depts. Laboratory Medicine, National Taiwan Univ. Hosp., Taipei, Taiwan R.O.C.

    Po-Ren Hsueh

  5. Centre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, 00100, Kenya

    Samuel Kariuki

  6. Dept. Biology, Haverford College, Lancaster Avenue 370, Haverford, 19041, U.S.A.

    Iruka N. Okeke

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Perlin, D.S. (2010). Antifungal Drug Resistance in Developing Countries. In: Sosa, A., Byarugaba, D., Amábile-Cuevas, C., Hsueh, PR., Kariuki, S., Okeke, I. (eds) Antimicrobial Resistance in Developing Countries. Springer, New York, NY. https://doi.org/10.1007/978-0-387-89370-9_9

Download citation

Publish with us

Policies and ethics

Search

Navigation